Overview of Retatrutide Retatrutide is classified as a triple-agonist research peptide , meaning it interacts with three distinct receptor pathways: GLP-1 receptors GIP receptors Glucagon receptors This broader receptor interaction is what differentiates Retatrutide from earlier peptide compounds and has led to increased interest within advanced research environments
[DOI] [PubMed] [Google Scholar] [60].McAllister DV, Wang PM, Davis SP, Park J-H, Canatella PJ, Allen MG, Prausnitz MR, Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies, Proceedings of the National Academy of Sciences 100(24) (2003) 1375513760
Reta (Research Grade)
Peptide medications, like most GLP-1 drugs, are especially challenging to deliver through the skins barrier because of their large molecular size
It uses a clever dual activation technique: directly boosting the GLP-1 pathway while optimizing your gut microbiome to produce more of those helpful SCFAs
After an online evaluation, patients can be prescribed compounded semaglutide, compounded tirzepatide, or compounded liraglutide depending on what a provider determines is appropriate
